A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at UCLA UCSD
- Dates
- study startedcompletion around
- Principal Investigator
- by Dawn S. Eliashiv, MD (ucla)

Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Dawn S. Eliashiv, MD (ucla)
Professor of Clinical, Neurology, Medicine. Authored (or co-authored) 41 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Biohaven Therapeutics Ltd.
- ID
- NCT06132893
- Phase
- Phase 2/3 Epilepsy Research Study
- Study Type
- Interventional
- Participants
- Expecting 390 study participants
- Last Updated